Credit Suisse’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $18M | Buy |
78,277
+16,621
| +27% | +$3.75M | 0.02% | 664 |
|
|
2023
Q4 | $13.6M | Buy |
61,656
+2,058
| +3% | +$474K | 0.01% | 795 |
|
|
2023
Q3 | $13.5M | Buy |
59,598
+1,970
| +3% | +$454K | 0.01% | 775 |
|
|
2023
Q2 | $12.7M | Buy |
57,628
+17,656
| +44% | +$3.91M | 0.01% | 822 |
|
|
2023
Q1 | $8.95M | Sell |
39,972
-1,422
| -3% | -$351K | 0.01% | 986 |
|
|
2022
Q4 | $11.5M | Buy |
41,394
+3,088
| +8% | +$780K | 0.01% | 867 |
|
|
2022
Q3 | $8.02M | Buy |
38,306
+1,157
| +3% | +$259K | 0.01% | 1014 |
|
|
2022
Q2 | $8.75M | Sell |
37,149
-1,742
| -4% | -$354K | 0.01% | 992 |
|
|
2022
Q1 | $6.98M | Buy |
38,891
+1,728
| +5% | +$329K | 0.01% | 1244 |
|
|
2021
Q4 | $8.03M | Sell |
37,163
-5,465
| -13% | -$1.07M | ﹤0.01% | 1668 |
|
|
2021
Q3 | $7.87M | Sell |
42,628
-17,664
| -29% | -$3.48M | ﹤0.01% | 1708 |
|
|
2021
Q2 | $10.8M | Sell |
60,292
-14,492
| -19% | -$2.76M | 0.01% | 1516 |
|
|
2021
Q1 | $12.5M | Sell |
74,784
-11,463
| -13% | -$1.91M | 0.01% | 1433 |
|
|
2020
Q4 | $13.1M | Sell |
86,247
-2,491
| -3% | -$327K | 0.01% | 1411 |
|
|
2020
Q3 | $8.96M | Buy |
88,738
+2,409
| +3% | +$264K | 0.01% | 1435 |
|
|
2020
Q2 | $10.4M | Buy |
86,329
+19,812
| +30% | +$2.23M | 0.01% | 1269 |
|
|
2020
Q1 | $6.31M | Sell |
66,517
-15,126
| -19% | -$1.44M | 0.01% | 1421 |
|
|
2019
Q4 | $7.19M | Buy |
81,643
+33,293
| +69% | +$2.93M | 0.01% | 1620 |
|
|
2019
Q3 | $3.85M | Sell |
48,350
-5,774
| -11% | -$465K | ﹤0.01% | 1966 |
|
|
2019
Q2 | $4.22M | Sell |
54,124
-33,752
| -38% | -$3.16M | ﹤0.01% | 1874 |
|
|
2019
Q1 | $10.3M | Sell |
87,876
-9,308
| -10% | -$1.08M | 0.01% | 1225 |
|
|
2018
Q4 | $10.6M | Sell |
97,184
-29,899
| -24% | -$3.47M | 0.01% | 1118 |
|
|
2018
Q3 | $16.3M | Buy |
127,083
+1,635
| +1% | +$202K | 0.01% | 988 |
|
|
2018
Q2 | $14.2M | Buy |
125,448
+12,467
| +11% | +$1.37M | 0.01% | 1040 |
|
|
2018
Q1 | $12.7M | Sell |
112,981
-5,271
| -4% | -$670K | 0.01% | 1112 |
|
|
2017
Q4 | $17.5M | Buy |
118,252
+13,947
| +13% | +$1.77M | 0.02% | 956 |
|
|
2017
Q3 | $12.2M | Buy |
104,305
+8,183
| +9% | +$1.05M | 0.01% | 1132 |
|
|
2017
Q2 | $12.5M | Sell |
96,122
-13,341
| -12% | -$1.66M | 0.01% | 1064 |
|
|
2017
Q1 | $14.8M | Buy |
109,463
+27,101
| +33% | +$4.11M | 0.01% | 994 |
|
|
2016
Q4 | $11.8M | Sell |
82,362
-46,579
| -36% | -$5.95M | 0.01% | 1099 |
|
|
2016
Q3 | $15.2M | Sell |
128,941
-6,170
| -5% | -$741K | 0.01% | 964 |
|
|
2016
Q2 | $14.3M | Sell |
135,111
-3,544
| -3% | -$395K | 0.02% | 951 |
|
|
2016
Q1 | $15.5M | Buy |
138,655
+577
| +0.4% | +$73K | 0.02% | 855 |
|
|
2015
Q4 | $21.6M | Sell |
138,078
-10,845
| -7% | -$1.58M | 0.02% | 736 |
|
|
2015
Q3 | $19.5M | Sell |
148,923
-99,375
| -40% | -$15.9M | 0.02% | 748 |
|
|
2015
Q2 | $43.2M | Buy |
248,298
+69,133
| +39% | +$12.4M | 0.04% | 488 |
|
|
2015
Q1 | $30.9M | Buy |
179,165
+29,412
| +20% | +$4.48M | 0.03% | 624 |
|
|
2014
Q4 | $19.4M | Buy |
149,753
+2,116
| +1% | +$273K | 0.02% | 898 |
|
|
2014
Q3 | $19M | Sell |
147,637
-25,940
| -15% | -$2.67M | 0.02% | 941 |
|
|
2014
Q2 | $15.4M | Buy |
173,577
+27,581
| +19% | +$2.65M | 0.01% | 1105 |
|
|
2014
Q1 | $13.7M | Buy |
145,996
+12,308
| +9% | +$1.26M | 0.01% | 1044 |
|
|
2013
Q4 | $15.1M | Buy |
133,688
+2,007
| +2% | +$181K | 0.01% | 996 |
|
|
2013
Q3 | $10.4M | Buy |
131,681
+12,045
| +10% | +$880K | 0.01% | 1108 |
|
|
2013
Q2 | $7.88M | Buy |
+119,636
| New | +$7.71M | 0.01% | 1285 |
|
Other funds holding UTHR
ACA
Credit Suisse's UTHR Position: Q1 2024 in Review
Credit Suisse increased its United Therapeutics (UTHR) stake by 27% in Q1 2024, buying an estimated $3.75M and bringing the position to 78,277 shares worth $18M. The position accounts for 0.02% of the portfolio, ranked #664.
Credit Suisse first reported a position in UTHR in Q2 2013 and has held it in 44 quarters since. The position peaked at $43.2M in Q2 2015. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.
- Credit Suisse held 78,277 shares of United Therapeutics worth $18M as of Q1 2024.
- Credit Suisse bought 16,621 United Therapeutics shares in Q1 2024, an estimated $3.75M.
- United Therapeutics made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #664 holding.
- Credit Suisse first reported a position in United Therapeutics in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's United Therapeutics position peaked at $43.2M in Q2 2015.
- 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.